Solventum Corporation/$SOLV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Solventum Corporation
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
- Ticker
- $SOLV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 20,584
- Headquarters
- Eagan, United States
- Website
- www.solventum.com
SOLV Metrics
BasicAdvanced
$15B
10.74
$8.19
0.69
-
Price and volume
Market cap
$15B
Beta
0.69
52-week high
$94.16
52-week low
$62.38
Average daily volume
890K
Financial strength
Current ratio
1.021
Quick ratio
0.501
Long term debt to equity
0.997
Total debt to equity
1.101
Interest coverage (TTM)
2.39%
Profitability
EBITDA (TTM)
1,074
Gross margin (TTM)
54.06%
Net profit margin (TTM)
17.26%
Operating margin (TTM)
6.84%
Effective tax rate (TTM)
15.45%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
2.70%
Return on equity (TTM)
33.96%
Valuation
Price to earnings (TTM)
10.744
Price to revenue (TTM)
1.842
Price to book
3.12
Price to tangible book (TTM)
-4.63
Price to free cash flow (TTM)
-129.733
Free cash flow yield (TTM)
-0.77%
Free cash flow per share (TTM)
-0.679
Growth
Revenue change (TTM)
-0.93%
Earnings per share change (TTM)
275.10%
3-year revenue growth (CAGR)
0.85%
3-year earnings per share growth (CAGR)
4.05%
What the Analysts think about SOLV
Analyst ratings (Buy, Hold, Sell) for Solventum Corporation stock.
Analyst projections of the future price of Solventum Corporation stock.
Bulls say / Bears say
Core product demand strengthened in the second quarter: MedSurg organic sales grew 8.9% and Dental Solutions grew 15.2%. That gives the turnaround a firmer base than growth in one business alone. (Solventum)
The 9.5% second-quarter organic growth figure was boosted by customer orders placed ahead of an ERP change, while the quarter’s profitability also benefited from a one-off tariff refund. Those items make the reported surge a poor guide to repeatable growth and earnings. (Solventum, Stock Titan)
Legal and balance-sheet burdens could limit financial flexibility: Solventum recorded $204 million of legal charges in the second quarter and had about $5.1 billion of debt against $403 million of cash at June-end. That leaves little room for setbacks while it funds its transformation. (Stock Titan)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.
SOLV Financial Performance
Revenues and expenses
SOLV Earnings Performance
Company profitability
Upcoming events
No upcoming events
SOLV News
AllArticlesVideos
Funds containing SOLV
AllEURGBPUSD
Fund name | Fund size | $SOLV weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.21% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.20% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.20% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.16% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.